Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders

Cancer Genetics and Cytogenetics

Volumn 199, Issue 2, 2010, Pages 110-120

  Canestraro, Martina ^a   Galimberti, Sara ^a   Savli, Hakan ^b   Palumbo, Giuseppe Alberto ^c   Tibullo, Daniele ^c   Nagy, Balint ^d   Guerrini, Francesca ^a   Piaggi, Simona ^e   Cine, Naci ^b   Metelli, Maria Rita ^f   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b KOCAELI UNIVERSITY   (Turkey)

^c UNIVERSITY OF CATANIA   (Italy)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e UNIVERSITY OF PISA   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 3; PROTEIN KINASE B;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; MITOCHONDRIAL PERMEABILITY; MYELOPROLIFERATIVE DISORDER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTO ONCOGENE; UBIQUITINATION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; BLAST CRISIS; BLOTTING, WESTERN; BORONIC ACIDS; CASPASE 8; CELL CYCLE; CELL PROLIFERATION; DRUG SYNERGISM; GENE EXPRESSION PROFILING; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELOPROLIFERATIVE DISORDERS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL;

EID: 77952775055     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.02.010     Document Type: Article

References (47)

1. Gazitt Y., Akay C. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology 2005, 10:205-213.
2. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
3. Amrán D., Sánchez Y., Fernández C., Ramos A.M., de Blas E., Bréard J., et al. Arsenic trioxide sensitizes promonocytic leukemia cells to TNFalpha-induced apoptosis via p38-MAPK-regulated activation of both receptor-mediated and mitochondrial pathways. Biochim Biophys Acta 2007, 1773:1653-1663.
4. Perkins C., Kim C.N., Fang G., Bhalla K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 2000, 95:1014-1022.
5. Munshi N.C., Tricot G., Desikan R., Badros A., Zangari M., Toor A., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002, 16:1835-1837.
6. Hussein M.A. Multiple myeloma: an update of developments in targeted therapy. Expert Rev Anticancer Ther 2005, 5:379-389.
7. Lee S.J., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., San Miguel J.F., et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008, 143:511-519.
8. Attar E.C., De Angelo D.J., Supko J.G., D'Amato F., Zahrieh D., Sirulnik A., et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008, 14:1446-1454.
9. Cortes J., Thomas D., Koller C., Giles F., Estey E., Faderl S., et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004, 10:3371-3376.
10. Orlowski R.Z., Voorhees P.M., Garcia R.A., Hall M.D., Kudrik F.J., Allred T., et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105:3058-3065.
11. Servida F., Soligo D., Delia D., Henderson C., Brancolini C., Lombardi L., et al. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 2005, 19:2324-2331.
12. Stapnes C., Døskeland A.P., Hatfield K., Ersvaer E., Ryningen A., Lorens J.B., et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukemia cells. Br J Haematol 2007, 136:814-828.
13. Conticello C., Adamo L., Vicari L., Giuffrida R., Iannolo G., Anastasi G., et al. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol 2008, 120:19-30.
14. Berenson J.R., Boccia R., Siegel D., Bozdech M., Bessudo A., Stadtmauer E., et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 2006, 135:174-183.
15. Birnie G.D. The HL60 cell line: a model system for studying human myeloid cell differentiation. Br J Cancer Suppl 1988, 9:41-45.
16. Yang Y.P., Liang Z.Q., Gao B., Jia Y.L., Qin Z.H. Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells. Acta Pharmacol Sin 2008, 29:123-134.
17. Seo T., Urasaki Y., Takemura H., Ueda T. Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines. Anticancer Res 2005, 25:991-998.
18. Tabellini G., Cappellini A., Tazzari P.L., Falà F., Billi A.M., Manzoli L., et al. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 2005, 202:623-634.
19. Fu Y.B., Sun Q.X., Meng F.Y., Xie J., Zhou G.B. Apoptosis of myeloid leukemia cell line HL60 induced by bortezomib, a proteasome inhibitor. Zhonghua Yi Xue Za Zhi 2006, 86:2413-2416.
20. An W.G., Hwang S.G., Trepel J.B., Blagosklonny M.V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14:1276-1283.
21. Shen Z.X., Chen G.Q., Ni J.H., Li X.S., Xiong S.M., Qiu Q.Y., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
22. 3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol 2006, 85:681-687.
23. Cai Y.X., Meng F.Y., Sun Q.X., Fu Y.B., Li L. In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells. Zhonghua Xue Ye Xue Za Zhi 2008, 29:737-740.
24. Yedjou C.G., Rogers C., Brown E., Tchounwou P.B. Differential effect of ascorbic acid and n-acetyl-l-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells. J Biochem Mol Toxicol 2008, 22:85-92.
25. Testi R., Mattii L., Di Simone D., Zaccaro L., Malvaldi G., Grassi B., et al. Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines. Leuk Res 1995, 19:257-261.
26. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991, 19:2499-2504.
27. Galimberti S., Canestraro M., Pacini S., Fazzi R., Orciuolo E., Trombi L., et al. PS-341 (bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 2008, 32:103-112.
28. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
29. Chou T.C. The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and antagonism in chemotherapy 1991, 61-102. Academic Press, San Diego. T.C. Chou, D.C. Rideout (Eds.).
30. Ling Y.H., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003, 278:33714-33723.
31. He Y., Yang J.M., Wang J.M., Zhou H., Lü S.Q., Hu X.X. Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008, 16:794-798.
32. Wen J., Feng Y., Huang W., Chen H., Liao B., Rice L., et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010, 34:85-92.
33. Sun Q.X., Meng F.Y., Fu Y.B., Li L., Tian S. HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:1022-1025.
34. Yan H., Wang Y.C., Li D., Wang Y., Liu W., Wu Y.L., et al. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia 2007, 21:1488-1495.
35. Del Poeta G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125-2131.
36. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
37. Cilloni D., Martinelli G., Messa F., Baccarani M., Saglio G. Nuclear factor κB as a target for new drug development in myeloid malignancies. Haematologica 2007, 92:1224-1229.
38. Jenkins C., Hewamana S., Gilkes A., Neelakantan S., Crooks P., Mills K., et al. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol 2008, 143:661-671.
39. Strair R.K., Gharibo M., Schaar D., Rubin A., Harrison J., Aisner J., et al. Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia. Clin Cancer Res 2008, 14:7564-7568.
40. Dy G.K., Thomas J.P., Wilding G., Bruzek L., Mandrekar S., Erlichman C., et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 2005, 11:3410-3416.
41. Flandrin P., Guyotat D., Duval A., Cornillon J., Tavernier E., Nadal N., et al. Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 2008, 13:357-364.
42. Buccisano F., Maurillo L., Tamburini A., Del Poeta G., Del Principe M.I., Ammatuna E., et al. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes. Eur J Haematol 2008, 80:107-114.
43. Lunghi P., Tabilio A., Pinelli S., Valmadre G., Ridolo E., Albertini R., et al. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. Hematol J 2001, 2:70-80.
44. + fraction of chronic myelogenous leukemias. Cancer Res 2000, 60:728-732.
45. Cilloni D., Messa F., Arruga F., Defilippi I., Gottardi E., Fava M., et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008, 93:921-924.
46. Candoni A., Tiribelli M., Toffoletti E., Cilloni D., Chiarvesio A., Michelutti A., et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009, 82:61-68.
47. Galimberti S., Guerrini F., Carulli G., Fazzi R., Palumbo G.A., et al. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004, 72:45-51.